ALK B — Alk-Abello A/S Share News
0.000.00%
Last trade - 00:00- DKK51.65bn
- DKK50.34bn
- DKK6.31bn
ALK-Abello jumps after raising FY outlook on strong tablet sales
Brief: ALK-Abello Outlook FY EBIT Margin 27%
Brief: ALK Expands Tablet Supply Partnership With Catalent
Europe Research Roundup: Capgemini, D'Ieteren Group SA, IAG
Brief: ALK-Abello Expects 2026 Revenue To Grow By 14-16%
Brief: ALK's ITULAZAX, ACARIZAX Recommended by NICE For Children With Allergic Rhinitis In UK
Europe Research Roundup: ALM. Brand, EFG International, Sampo
Brief: Alk-Abello's EURneffy 1 Mg Gets Approval In U.K.
Berenberg starts ALK-Abello at buy on 'transformative' allergy push
Brief: Alk-Abello Q1 EBIT Up At DKK 570 Million
Brief: ALK-Abello Outlook FY EBIT Margin 26%
Alaska Air slips after pulling annual profit forecast
ALK-Abello rises on positive Phase 2 peanut allergy trial data
Brief: ALK-Abello Announces Successful Outcome Of Phase 2 Trial Of Peanut Allergy Tablet
Brief: ALK-Abello Says Neffy Approved In Canada
Raymond James cuts Alaska Air's PT, cites fuel costs
Brief: ALK-Abello Says EURneffy 1 mg Approved Across The EU
Brief: Alk-Abello Recommends DKK 355 Mln Dividend Payments For 2025
Denmark's ALK-Abello Q4 revenue rises 17% on higher tablet sales